Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
123.07
-0.22 (-0.18%)
Nov 4, 2024, 4:00 PM EST - Market closed
Sarepta Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 1,505 | 1,243 | 933.01 | 701.89 | 540.1 | 380.83 | Upgrade
|
| Revenue Growth (YoY) | 49.98% | 33.26% | 32.93% | 29.96% | 41.82% | 26.51% | Upgrade
|
| Cost of Revenue | 946.21 | 1,028 | 1,017 | 862.13 | 785.63 | 617.3 | Upgrade
|
| Gross Profit | 558.78 | 215.61 | -84.07 | -160.24 | -245.53 | -236.46 | Upgrade
|
| Selling, General & Admin | 518.39 | 481.87 | 451.42 | 282.66 | 317.88 | 284.81 | Upgrade
|
| Operating Expenses | 520.8 | 483.43 | 452.14 | 283.37 | 318.54 | 285.66 | Upgrade
|
| Operating Income | 37.99 | -267.82 | -536.2 | -443.61 | -564.06 | -522.12 | Upgrade
|
| Interest Expense | -19.46 | -22.01 | -53.25 | -63.53 | -59.95 | -30.67 | Upgrade
|
| Interest & Investment Income | 33.73 | 36.26 | 16.49 | 0.35 | 2.97 | 7.24 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.93 | 0.62 | -6.92 | -0.94 | 0.52 | -0.24 | Upgrade
|
| EBT Excluding Unusual Items | 54.19 | -252.96 | -579.88 | -507.72 | -620.52 | -545.79 | Upgrade
|
| Gain (Loss) on Sale of Investments | 20.14 | 19.39 | 8.66 | -4.33 | 4.49 | 15.35 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 102 | - | 102 | 108.07 | - | Upgrade
|
| Asset Writedown | - | - | - | - | -0.1 | -0.2 | Upgrade
|
| Other Unusual Items | -12.1 | -388.53 | -118.74 | -8.9 | -45 | -10 | Upgrade
|
| Pretax Income | 62.22 | -520.1 | -689.96 | -418.95 | -553.07 | -713.88 | Upgrade
|
| Income Tax Expense | 14.93 | 15.88 | 13.53 | -0.17 | 1.06 | 1.2 | Upgrade
|
| Net Income | 47.3 | -535.98 | -703.49 | -418.78 | -554.13 | -715.08 | Upgrade
|
| Net Income to Common | 47.3 | -535.98 | -703.49 | -418.78 | -554.13 | -715.08 | Upgrade
|
| Shares Outstanding (Basic) | 95 | 92 | 88 | 81 | 78 | 74 | Upgrade
|
| Shares Outstanding (Diluted) | 98 | 92 | 88 | 81 | 78 | 74 | Upgrade
|
| Shares Change (YoY) | 10.93% | 5.53% | 7.75% | 4.24% | 5.90% | 11.12% | Upgrade
|
| EPS (Basic) | 0.50 | -5.80 | -8.03 | -5.15 | -7.11 | -9.71 | Upgrade
|
| EPS (Diluted) | 0.49 | -5.80 | -8.03 | -5.15 | -7.11 | -9.71 | Upgrade
|
| Free Cash Flow | -506.82 | -577.1 | -356.17 | -481.66 | 25.26 | -516.09 | Upgrade
|
| Free Cash Flow Per Share | -5.19 | -6.25 | -4.07 | -5.93 | 0.32 | -7.01 | Upgrade
|
| Gross Margin | 37.13% | 17.34% | -9.01% | -22.83% | -45.46% | -62.09% | Upgrade
|
| Operating Margin | 2.52% | -21.54% | -57.47% | -63.20% | -104.44% | -137.10% | Upgrade
|
| Profit Margin | 3.14% | -43.11% | -75.40% | -59.66% | -102.60% | -187.77% | Upgrade
|
| Free Cash Flow Margin | -33.68% | -46.42% | -38.17% | -68.62% | 4.68% | -135.52% | Upgrade
|
| EBITDA | 77.75 | -223.43 | -494.34 | -405.59 | -537.6 | -498.07 | Upgrade
|
| EBITDA Margin | 5.17% | -17.97% | -52.98% | -57.79% | -99.54% | -130.79% | Upgrade
|
| D&A For EBITDA | 39.76 | 44.4 | 41.86 | 38.02 | 26.46 | 24.05 | Upgrade
|
| EBIT | 37.99 | -267.82 | -536.2 | -443.61 | -564.06 | -522.12 | Upgrade
|
| EBIT Margin | 2.52% | -21.54% | -57.47% | -63.20% | -104.44% | -137.10% | Upgrade
|
| Revenue as Reported | 1,505 | 1,243 | 933.01 | 701.89 | 540.1 | 380.83 | Upgrade
|
| Advertising Expenses | - | 28.6 | 14.6 | 7.7 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.